Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring.

Exogenous addition of neutralising antibody to transforming growth factor-beta 1,2 to cutaneous wounds in adult rodents reduces scarring. Three isoforms of transforming growth factor-beta (1, 2 and 3) have been identified in mammals. We investigated the isoform/isoforms of TGF-beta responsible for cutaneous scarring by: (i) reducing specific endogenous TGF-beta isoforms by exogenous injection of isoform specific neutralising antibodies; and (ii) increasing the level of specific TGF-beta isoforms by exogenous infiltration into the wound margins. Exogenous addition of neutralising antibody to TGF-beta 1 plus neutralising antibody to TGF-beta 2 reduced the monocyte and macrophage profile, neovascularisation, fibronectin, collagen III and collagen I deposition in the early stages of wound healing compared to control wounds. Treatment with neutralising antibodies to TGF-betas 1 and 2 markedly improved the architecture of the neodermis to resemble that of normal dermis and reduced scarring while the control wounds healed with scar formation. Exogenous addition of neutralising antibody to TGF-beta 1 alone also reduced the monocyte and macrophage profile, fibronectin, collagen III and collagen I deposition compared to control wounds. However, treatment with neutralising antibody to TGF-beta 1 alone only marginally reduced scarring. By contrast, wounds treated with neutralising antibody to TGF-beta 2 alone did not differ from control wounds. Interestingly, exogenous addition of the TGF-beta 3 peptide also reduced the monocyte and macrophage profile, fibronectin, collagen I and collagen III deposition in the early stages of wound healing and markedly improved the architecture of the neodermis and reduced scarring. By contrast, wounds treated with either TGF-beta 1 or with TGF-beta 2 had more extracellular matrix deposition in the early stages of wound healing but did not differ from control wounds in the final quality of scarring. This study clearly demonstrates isoform specific differences in the role of TGF-betas in wound healing and cutaneous scarring. TGF-beta 1 and TGF-beta 2 are implicated in cutaneous scarring. This study also suggests a novel therapeutic use of exogenous recombinant, TGF-beta 3 as an anti-scarring agent.

[1]  M. Ferguson,et al.  The extracellular matrix of lip wounds in fetal, neonatal and adult mice. , 1991, Development.

[2]  W. Newman,et al.  Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro. , 1991, The American journal of pathology.

[3]  M. Dickinson,et al.  In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2. , 1990, Development.

[4]  L. Madisen,et al.  Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2 , 1989, Molecular and cellular biology.

[5]  C. Heldin,et al.  Effects of homodimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat. , 1992, The Journal of surgical research.

[6]  C. Heldin,et al.  Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. , 1990, The Journal of clinical investigation.

[7]  T. Colby,et al.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Sporn,et al.  Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. , 1987, Science.

[9]  C. Heldin,et al.  Platelet-derived growth factors: A family of isoforms that bind to two disticnt receptors , 1989 .

[10]  M. Sporn,et al.  Regulation of expression of transforming growth factor-β2 by transforming growth factor-β isoforms is dependent upon cell type , 1992 .

[11]  R. Akhurst,et al.  Expression of TGF-beta isoforms during first trimester human embryogenesis. , 1990, Development.

[12]  D. Foreman,et al.  Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. , 1994, Journal of cell science.

[13]  P. Schmid,et al.  Differential expression of TGF beta 1, beta 2 and beta 3 genes during mouse embryogenesis. , 1991, Development.

[14]  J. McPherson,et al.  Exogenous transforming growth factor-beta 2 enhances connective tissue formation and wound strength in guinea pig dermal wounds healing by secondary intent. , 1990, Annals of surgery.

[15]  S. Wahl,et al.  TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes. , 1990, Growth factors.

[16]  R. Derynck,et al.  Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. , 1993, Science.

[17]  R. Auerbach,et al.  Regional differences in the growth of normal and neoplastic cells. , 1982, Science.

[18]  M. Sporn,et al.  Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. , 1989, The Journal of clinical investigation.

[19]  S. Mohan,et al.  Comparison of the biological actions of TGF beta‐1 and TGF beta‐2: Differential activity in endothelial cells , 1988, Journal of cellular physiology.

[20]  M. Sporn,et al.  Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.

[21]  R. Derynck,et al.  Human Transforming Growth Factor- β3: Recombinant Expression, Purification, and Biological Activities in Comparison with Transforming Growth Factors-β 1 and -β2 , 1989 .

[22]  P. Kondaiah,et al.  Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo. , 1991, Development.

[23]  M. Sporn,et al.  Sandwich Enzyme-Linked Immunosorbent Assays (Selisas) Quantitate and Distinguish Two Forms of Transforming Growth Factor-Beta (TGF-β1 and TGF-β2) in Complex Biological Fluids , 1989 .

[24]  M. Sporn,et al.  Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. , 1983, Science.

[25]  R. Coffey,et al.  Regulation of epithelial cell proliferation by transforming growth factors , 1989, Journal of cellular biochemistry.

[26]  D. Foreman,et al.  Control of scarring in adult wounds by neutralising antibody to transforming growth factor β , 1992, The Lancet.

[27]  J. Prieto,et al.  Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. , 1991, The New England journal of medicine.

[28]  M. Sporn,et al.  Mesoderm induction in Xenopus laevis distinguishes between the various TGF-beta isoforms. , 1990, Growth factors.